贺维斯特医药科技 HiRO的动态

Find out more about this and the key trends and standout deals shaping the pharmaceutical industry.

The IQVIA Pharma Deals Half Year Review of 2024 reveals important trends in the pharmaceutical sector's mergers, acquisitions (M&A), and licensing activities. Although the number of M&A deals dropped by 20% compared to the first half of 2023, the total value of these deals increased significantly. This shows that big pharmaceutical companies, like Johnson & Johnson, Merck & Co., and Gilead Sciences, are focusing on larger, more strategic acquisitions, especially in the areas of oncology and immunology. Licensing deals also saw a change. While the number of deals fell by 24%, the overall value went up by 22%. This suggests that companies are more interested in securing high-value, later-stage products rather than a large number of early-stage assets. Oncology remained the top focus for deals, driven by advances in immuno-oncology and new treatments like radiopharmaceuticals. Looking ahead, the report predicts that deal-making will continue, particularly as many major drug patents are set to expire. This will push companies to look for new, innovative therapies through acquisitions and partnerships. Although regulatory issues may limit some large deals, targeted acquisitions and licensing agreements will likely remain a key strategy for future growth. For more detailed insights, IQVIA provides a comprehensive analysis on this topic. #pharma #pharmadevelopment #pharmadeals #strategy #pharmastrategy #pharmalicensing #pharmaceuticalstrategy

Licensing deal volume was down, yet value was up in H1 2024. Discover how this trend is reshaping the competitive landscape in drug development. Download the #PharmaDeals H1 Review of 2024 to find out more https://bit.ly/4gNZQrl #PharmaLicensing #PharmaceuticalStrategy

TODAY! Join us for the free Expert Insights webinar: Type II Drug Master Files for Early-Stage, Small Molecule, Drug Development. ?? Have questions on managing administrative components, regulatory documentation, and holder obligations of Type II DMFs? ?? Face challenges determining what CMC information is sufficient for each phase of the investigation? ?? Lack clarity on how to navigate the industry requirements for organizing the DMF content to ensure technical compliance with FDA’s Submissions Standards Catalog? Answering these questions is an esteemed panel of regulatory minds, including Margaret Studzinska, Christine A. Clarke, PhD and Sandra Atkins. Don't miss out - This is your last chance to register: https://hubs.li/Q02qHXw80 #DMF #DrugMasterFile #DrugDevelopment #eCTD #RegulatorySubmission #Pharma

We just released our July Pipeline Report! ??? This comprehensive report offers insights into recent drug approvals, products on our radar, and more! ????Get your hands on the full report: https://bit.ly/4frsUEg #pipelinereport #newmedications #fdaapproved #specialtypharmacy

We just released our July Pipeline Report! ??? This comprehensive report offers insights into recent drug approvals, products on our radar, and more! ????Get your hands on the full report: https://bit.ly/3A2wTXA #pipelinereport #newmedications #fdaapproved #specialtypharmacy

In this webinar, by International Society of Pharmacometrics , our Martin Bergstrand, Ph.D. presents how MIDD can support new drug applications, from informing trial design, to providing evidence of the drug’s safety and effectiveness for regulatory decision-making. Register via ISOP’s homepage, see link below. #pharmaceutical #sciencecommunication #lifesciences #drugdevelopment

4 Drug Development Strategies To Accelerate Commercialization https://buff.ly/4a9nqL1 #drugdevelopment #clinicaldevelopment #clinicaltrials

Are you navigating the complexities of regulatory submissions? At MMS, we’re here to help! Our expert team specializes in providing tailored support to streamline your submission process and ensure compliance. With our in-depth knowledge and experience, we’ll guide you every step of the way. Don’t go it alone - reach out to me today and let’s work together to achieve your regulatory goals! #RegulatoryAffairs #Compliance #MMS #Pharma #Biotech

? How can we revolutionize drug approvals and speed up innovation? After analyzing 20 years of FDA drug approvals, we've uncovered the hurdles in drug development: ?? How can we generate trustworthy efficacy data faster to keep up with accelerated approvals? ?? How can drug developers prioritize their portfolios more effectively? ?? How can we better collaborate with regulators to provide them with the right tools for decision-making? The EMA’s qualification of #SV95C as a primary #digitalendpoint for #clinicaltrials paves the way for better answers to these less attention-grabbing questions and for a silent (r)evolution in drug development. At Sysnav Healthcare, our mission is to provide meaningful real world data to accelerate medical progress.